Blog

ASLS wins the NH Tech Alliance Product of the Year award for 2025, recognizing the BioAssembly™ Platform as a breakthrough in 3D bioprinting and automated tissue manufacturing.

Discover best practices for streamlining complex organoid research with automation. Learn how Advanced Solutions Life Sciences combines robotics, software intelligence, and optimized fluidics to improve reproducibility, scalability, and experimental reliability.

In 2000, President & CEO Michael W. Golway, P.E., wrote, “Use my entrepreneurial opportunity to do something profound and positive.” 25 years later, that vision has fueled innovations like the BioAssemblyBot®, supported businesses through challenges, and advanced life-changing science. Join us in celebrating his 25-year journey — and looking ahead to a future that’s even more profound and positive.

As NAMs models such as organoids gain traction across disease modeling, drug discovery, and personalized medicine, one major challenge persists - scaling high-throughput organoid screening efficiently and reproducibly.

At Advanced Solutions Life Sciences (ASLS), we believe technology can help restore what cancer takes away - offering new possibilities for healing, confidence, and quality of life. This Breast Cancer Awareness Month, we’re proud to spotlight our global partners who are making profound and positive impacts in the fight against breast cancer, powered by our BioAssemblyBot™ platform.

Hands-Off to Organoid Assays! Manual organoid workflows often mean inconsistent results, lost time, and limited scale. Learn the top pitfalls of manual handling—and how Advanced Solutions’ BioAssemblyBot® platforms eliminate them with precision automation.

We’re honored to have been featured in Dr. Carolyn Clancy’s recent talk at the Advanced Regenerative Manufacturing Institute (ARMI) | BioFabUSA Meeting in the Millyard. Dr. Clancy’s presentation highlighted the important strides being made in regenerative medicine and personalized therapies for America’s veterans - an initiative we’re proud to support.

A Historic NIH Decision That Changes the Research Landscape On July 7, 2025, the National Institutes of Health (NIH) announced it will no longer issue new funding opportunities that focus exclusively on animal models. From now on, all new NIH grant announcements must include - or allow for - human-relevant research approaches, often referred to as New Approach Methodologies (NAMs).    This shift means researchers seeking NIH funding must incorporate methods like organoids,...

Profound and Positive Podcast We’re excited to announce the launch of our brand-new podcast series, Profound and Positive   - where we explore how Advanced Solutions’ technologies are making profound and positive impacts on scientific discovery and biomedical research! Our mission with this series is simple: to open the lab doors and share real stories from scientists, engineers, and innovators who are pushing the boundaries of what’s possible. Each episode will feature conve

Organoid360™ is a turnkey automation platform designed for modern 3D biology and organoid research. Built on the BioAssemblyBot® and pre-configured with plug-and-play BioApps®, Organoid360 enables reproducible, high-throughput organoid workflows with minimal setup. Researchers can accelerate organoid assays, drug screening, and discovery while reducing hands-on time and variability.

Hannah A. Strobel, PhD | Staff Scientist | Advanced Solutions Life Sciences  Victoria Marsh, PhD | Director, Custom Organoid Services | Molecular Devices  Maria R. Oyaga, PhD | Scientist | Core Life Analytics  Angeline Lim, PhD | Applications Scientist | Molecular Devices    Introduction:   Patient-derived organoids (PDOs) are transforming how we approach drug and therapy development, offering more predictive models of patient responses. However, effectively utilizing these c

Advanced Solutions Life Sciences is thrilled to announce the launch of BioApp Intelligence. This new software is a groundbreaking AI-driven solution designed to revolutionize laboratory automation and 3D Bioprinting. When paired with the powerful BioAssemblyBot® (BAB) Platform - the possibilities are endless. Overview BioApps Intelligence is an AI product that, coupled with the  BioAssemblyBot® (BAB) Platform, empowers laboratories to automate simple and complex laboratory w

Discover how the BioAssemblyBot 400 advances cancer therapy by automating the precise fabrication of AS1411-conjugated gold nanopartic

Discover the latest advancements in T-cell immunotherapies for cancer treatment.

Discover how single cell dispensing is transforming life sciences research. The BioAssemblyBot® Hand | SCD automates precise dispensing of individual cells, boosting efficiency and reproducibility for gene editing, clonal expansion, antibody development, and more. Integrated with BioApps™, this solution streamlines workflows and accelerates impactful discoveries in modern labs.

Advanced Solutions Life Sciences (ASLS) and Epson Robots have revolutionized biotechnology with the BioAssemblyBot (BAB), a platform that...

Advanced Solutions introduces the Single Cell Dispense BAB Hand. Paired with BioApps(TM), the Single Cell Dispense BAB Hand enables a workflow that improves the efficiency and accuracy of single cell analysis. The Single Cell Dispense BAB Hand works on all BAB Models, including the BAB500, BAB400, and BAB200.

Brown University through a grant by the Department of Defense (DOD) has developed a novel automated tissue manufacturing process using BAB.

This blog post discusses a study conducted by Advanced Solutions using a 3D in vitro model

Tissue organoids, also known as "mini organs," possess vast potential as tools for various applications, such as disease modeling, drug screening, and tissue engineering. To effectively imitate the native tissue environment, it is essential to integrate a microvasculature with the parenchyma and stroma.